MedPath

Safety, Efficacy and Acceptability of Flavocoxid (Limbrel)A Pilot Study

Not Applicable
Completed
Conditions
Osteoarthritis
Interventions
Dietary Supplement: flavocoxid
Registration Number
NCT00303017
Lead Sponsor
Primus Pharmaceuticals
Brief Summary

safety, efficacy and acceptability of Flavocoxid

Detailed Description

Safety, Efficacy and acceptability of Flavocoxid (Limbrel) compared with Naproxen in Subjects with Osteoarthritis of the Knee. A Pilot Study

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria

OA of the knee,K-L grade 2-3 in general good health is currently taking an NSAID or COX-2 inhibitor -

Exclusion Criteria

pregant or nursing women grade 1 or 4 OA any significant medical condition that in the opinion of the physician might put the subject at risk in this study any form of arthropathy other than OA any condition that might confound the evaluation of the pain, stiffness or function of the target joint intra-articular cotticosteroid inkection in the target joint within 3 month of the screening visit concomitant use of other anti-inflammatory or anti arthritic medication or products(including OTC and herbal preparations) Low dose aspirin for cardio-protection is allowed concomitant use of coumadin or other anticoagulant or anti-platelet medication concomitant use of gastro-protectiv medications including, but not limited to, H2 blockers and proton pump inhibitors, including OTC and herbal products History of allergy to Flavonoids

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
flavocoxidflavocoxidmedical food
naproxenNaproxenNSAID
Primary Outcome Measures
NameTimeMethod
compare efficacy
Secondary Outcome Measures
NameTimeMethod
evaluate safety

Trial Locations

Locations (1)

Timothy Truitt MD

🇺🇸

Melbourne, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath